Table 2. Association between polymorphisms in DNA repair and cell-cycle genes and risk of developing late skin toxicity (telangiectasia) with score ⩾2 after radiotherapy.

		Patients without telangiectasia		Patients with telangiectasia
Gene polymorphism	Genotype	N=278	%	N=131	%	ORa	95% CI
APEX1	TT	71	25.9	39	30.7	1.00
Asp148Gln	TG	134	48.9	65	51.2	1.03	0.58–1.83
rs3136820	GG	69	25.2	23	18.1	0.66	0.33–1.32
	TG+GG	203	74.1	88	69.3	0.90	0.53–1.54
XRCC1	TT	94	34.2	43	33.9	1.00
−77 T>C	TC	136	49.5	54	42.5	0.97	0.56–1.67
rs3213245	CC	45	16.4	30	23.6	1.87	0.94–3.70
	TC+CC	181	65.8	84	66.1	1.17	0.71–1.95
XRCC1	CC	242	88.3	117	92.1	1.00
Arg194Trp	CT	30	11	10	7.9	0.58	0.24–1.40
rs1799782	TT	2	0.7	0	0	0	0
	CT+TT	32	11.7	10	8	0.57	0.24–1.38
XRCC1	GG	244	88.4	118	92.9	1.00
Arg280His	GA	30	10.9	9	7.1	0.49	0.19–1.24
rs25489	AA	2	0.7	0	0	0	0
	GA+AA	32	11.6	9	7.1	0.43	0.17–1.09
XRCC1	GG	112	40.6	50	39.4	1.00
Arg399Gln	GA	120	43.5	63	49.6	1.09	0.65–1.82
rs25487	AA	44	15.9	14	11	0.63	0.29–1.37
	GA+AA	164	59.4	77	60.6	0.96	0.59–1.57
XRCC2	GG	236	85.5	113	89	1.00
Arg188His	GA	38	13.8	13	10.2	0.83	0.39–1.76
rs3218536	AA	2	0.7	1	0.8	1.05	0.08–13.93
	GA+AA	40	14.5	14	11	0.84	0.41–1.74
XRCC3	CC	104	38	45	35.4	1.00
Thr241Met	CT	126	46	63	49.6	1.05	0.62–1.79
rs861539	TT	44	16.1	19	15	1.12	0.53–2.40
	CT+TT	170	62	82	64.6	1.07	0.65–1.77
NBS1	GG	120	43.5	53	41.7	1.00
Glu185Gln	GC	137	49.6	58	45.7	0.92	0.55–1.54
rs1805794	CC	19	6.9	16	12.6	2.14	0.88–5.19
	GC+CC	156	56.5	74	58.3	1.06	0.65–1.72
XPD	GG	120	43.8	42	33.3	1.00
Asp312Asn	GA	117	42.7	69	54.8	1.51	0.89–2.55
rs1799793	AA	37	13.5	15	11.9	0.91	0.41–2.01
	GA+AA	154	56.2	84	66.6	1.36	0.82–2.24
XPD	AA	109	39.6	42	33.3	1.00
Lys751/Gln	AC	133	48.4	65	51.6	1.15	0.68–1.95
rs13181	CC	33	12	19	15.1	1.21	0.57–2.58
	AC+CC	166	60.4	84	66.6	1.16	0.70–1.92
P21	CC	242	87.7	110	86.6	1.00
Ser31Arg	CA	31	11.2	17	13.4	1.54	0.71–3.32
rs1801270	AA	3	1.1	0	0	0	0
	CA+AA	34	12.3	17	13.4	1.27	0.60–2.68
TP53	GG	160	58.0	64	50.4	1.00
Arg72Pro	GC	96	34.8	49	38.6	1.67	0.98–2.83
rs1042522	CC	20	7.3	14	11	1.62	0.71–3.70
	GC+CC	116	40	63	49.6	1.66	1.02–2.71
TP53	A1A1	214	77.6	87	68.5	1.00
PIN3	A1A2	56	20.3	40	31.5	2.14	1.23–3.71
	A2A2	6	2.2	0	0	0	0
	A1A2+A2A2	62	22.4	40	31.5	1.95	1.13–3.37

CI=confidence interval; NTD=normalised total dose; OR=odds ratio.

^aAdjusted for NTD, age at the time of late toxicities evaluation, time since radiotherapy (months), clinic, acute skin toxicity, high blood pressure, allergy, pack-years (never, <20, ⩾20), skin type (always/moderate/seldom sunburn), clinic, marital status (single/divorced/widowed, married/partner).